CRM197 treatment sensitized the paclitaxel‐resistant ovarian cancer to paclitaxel, at least in part, via NAC‐1 and its downstream Gadd45gip1/ Gadd45 pathway in A2780/Taxol and SKOV3/Taxol cells. This evidence concerns the gene GADD45A and ovarian cancer.